Spontaneous, anecdotal, retrospective, open‐label study on the efficacy, safety and tolerability of cannabis galenical preparation (Bedrocan)

Objectives Our main aim was to investigate the short‐term therapeutic effects, safety/tolerability and potential side effects of the cannabis galenical preparation (Bedrocan) in patients with a range of chronic conditions unresponsive to other treatments. Methods In this retrospective, ‘compassionate use’, observational, open‐label study, 20 patients (age 18–80 years) who had appealed to our ‘Second Opinion Medical Consulting Network’ (Modena, Italy), were instructed to take sublingually the galenical oil twice a day for 3 months of treatment. The usual starting dose was low (0.5 ml/day) and gradually titrated upward to the highest recommended dose (1 ml/day). Tolerability and adverse effects were assessed at baseline and monthly thereafter during the treatment period through direct contact (email or telephone) or visit if required. Patients’ quality of life was evaluated at baseline and 3 months using the medical outcome short‐form health survey questionnaire ( SF ‐36). Key findings From baseline to 6 months post‐treatment, SF ‐36 scores showed: reductions in total pain ( P  < 0.03); improvements in the physical component ( P  < 0.02); vitality ( P  < 0.03); social role functioning ( P  < 0.02); and general health state ( P  < 0.02). No changes in role limitations ( P  = 0.02) due to emotional state (e.g. panic, depression, mood alteration) were reported. Monthly reports of psychoactive adverse effects showed significant insomnia reduction ( P  < 0.03) and improvement in mood ( P  < 0.03) and concentration ( P  < 0.01). Conclusions These data suggest that a cannabis galenical preparation may be therapeutically effective and safe for the symptomatic treatment of some chronic diseases. Further studies on the efficacy of cannabis as well as cannabinoid system involvement in the pathophysiology are warranted.